Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • longfcel longfcel Feb 14, 2013 12:54 PM Flag

    In CKD patients, Epogen = 5% adverse effects?

    (CKD patients, are Omonty's patients).

    From Epogen's "data sheet" (can't paste link):
    "Patients with CKD: Adverse reactions in ≥ 5% of Epogen-treated patients
    in clinical studies were hypertension, arthralgia, muscle spasm, pyrexia,
    dizziness, medical device malfunction, vascular occlusion, and upper
    respiratory tract infection (6.1)".

    ----
    Ok, don't call me pumper, not yet.
    Surely I'm missing something.
    That Epo's "5%"...... must be compared with Omonty's 1:1000?

    Again, What am I missing?
    (the above line, is taken from Epogen bottle... can't paste link).
    tx

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Only serious investors.
      - On EPOGEN papers: in CKD patients, I found a "5%" in adverse side effects. This is a 20-years-old data of course..... not an hidden data somebody found on the web.
      - today they told Omontys does have a 1:1000 adverse side effects (=0.1%).

      Now they said: "we pause pilot project to evaluate data.... both safety and efficacy".

      Then, they said: "every patients under Omonty can go on with therapy, because is DOING WELL".

      On Efficacy (no numbers given)---------- IT'S DOING WELL
      On Safety: adverse effects 5% (EPO) Vs 0.1%(Omonty).

      Is there something missing?

    • yep, this Omontys news (or non-news) was just a standard procedure thing, and will pop over $20 when there is further update on this. Every drug, to include aspirin (mentioned earlier) has potential non-life threatening side effects, like headache, nausea, skin rash, etc....I would not short this stock here.

 
AFFY
0.0853+0.0003(+0.35%)Feb 5 3:53 PMEST